Leukemia Research
Volume 29, Issue 2 , Pages 141-146 , February 2005

BCRP mRNA expression v. clinical outcome in 40 adult AML patients

  • Bertil Uggla

      Affiliations

    • Department of Medicine, Örebro University Hospital, 701 85 Örebro, Sweden
    • Karolinska Institute, Stockholm, Sweden
    • Corresponding Author InformationCorresponding author. Tel.: +46 19 602 1000; fax: +46 602 45 80.
    • ,
  • Elisabet Ståhl

      Affiliations

    • Clinical Research Centre, Örebro University Hospital, 701 85 Örebro, Sweden
    • ,
  • Dick Wågsäter

      Affiliations

    • Department of Caring Science, Örebro University, 701 85 Örebro, Sweden
    • ,
  • Christer Paul

      Affiliations

    • Department of Haematology, Huddinge University Hospital, Stockholm, Sweden
    • Karolinska Institute, Stockholm, Sweden
    • ,
  • Mats G. Karlsson

      Affiliations

    • Department of Pathology, Örebro University Hospital, 701 85 Örebro, Sweden
    • ,
  • Allan Sirsjö

      Affiliations

    • Department of Caring Science, Örebro University, 701 85 Örebro, Sweden
    • ,
  • Ulf Tidefelt

      Affiliations

    • Department of Medicine, Örebro University Hospital, 701 85 Örebro, Sweden
    • Department of Clinical Medicine, Örebro University, Örebro, Sweden

Received 20 January 2004 ,Accepted 4 June 2004.

References 

  1. McKenna SL, Padua RA. Multidrug resistance in leukaemia. Br J Haematol. 1997;96:659–674
  2. Sonneveld P, List AF. Chemotherapy resistance in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14:211–233
  3. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A. 1998;95:15665–15670
  4. Chen Y-N, Mickley LA, Schwartz AM, Acton EM, Hwang J, Fojo A. Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem. 1990;265:10073–10080
  5. Litman T, Brangi M, Hudson E, et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci. 2000;113:2011–2021
  6. Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood. 2002;99:507–512
  7. Wulf GG, Wang RY, Kuehnle I, et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood. 2001;98:1166–1173
  8. Goodell MA, Rosenzweig M, Kim H, et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med. 1997;3:1337–1345
  9. Ross DD, Karp JE, Chen TT, Doyle LA. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood. 2000;96:365–368
  10. Abbott BL, Colapietro AM, Barnes Y, Marini F, Andreeff M, Sorrentino BP. Low levels of ABCG2 expression in adult AML blast samples. Blood. 2002;100:4594–4601
  11. Steinbach D, Sell W, Voigt A, Hermann J, Zintl F, Sauerbrey A. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia. 2002;16:1443–1447
  12. van den Heuvel-Eibrink MM, Wiemer EA, Prins A, et al. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia. 2002;16:833–839
  13. van der Kolk DM, Vellenga E, Scheffer GL, et al. Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood. 2002;99:3763–3770
  14. van der Pol M, Broxterman H, Pater J, et al. Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute leukemia. Haematologica. 2003;88:134–147
  15. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322–2333
  16. Honjo Y, Hrycyna CA, Yan QW, et al. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res. 2001;61:6635–6639
  17. Komatani H, Kotani H, Hara Y, et al. Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. Cancer Res. 2001;61:2827–2832
  18. Nakanishi T, Karp JE, Tan M, et al. Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients. Clin Cancer Res. 2003;9:3320–3328
  19. Sargent JM, Williamson CJ, Maliepaard M, Elgie AW, Scheper RJ, Taylor CG. Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. Br J Haematol. 2001;115:257–262

PII: S0145-2126(04)00228-0

doi: 10.1016/j.leukres.2004.06.004

Leukemia Research
Volume 29, Issue 2 , Pages 141-146 , February 2005

Article Tools

* Image Usage & Resolution